The patatin-like lipase family in *Gallus gallus*

Jani Saarela1,2, Gerlinde Jung1, Marcela Hermann1, Johannes Nimpf1 and Wolfgang J Schneider*1

Address: 1The Max F. Perutz Laboratories, Department of Medical Biochemistry, Medical University of Vienna, Dr. Bohr Gasse 9/2, A-1030 Vienna, Austria and 2National Public Health Institute and FIMM, Institute for Molecular Medicine Finland, Haartmaninkatu 8, 00290 Helsinki, Finland

Email: Jani Saarela - jani.saarela@ktl.fi; Gerlinde Jung - gerlinde.jung@vu-wien.ac.at; Marcela Hermann - marcela.hermann@meduniwien.ac.at; Johannes Nimpf - johannes.nimpf@meduniwien.ac.at; Wolfgang J Schneider* - wolfgang.schneider@meduniwien.ac.at

* Corresponding author

**Abstract**

**Background:** In oviparous species, genes encoding proteins with functions in lipid remodeling, such as specialized lipases, may have evolved to facilitate the assembly and utilization of yolk lipids by the embryo. The mammalian gene family of patatin-like phospholipases (PNPLAs) has received significant attention, but studies in other vertebrates are lacking; thus, we have begun investigations of PNPLA genes in the chicken (*Gallus gallus*).

**Results:** We scanned the draft chicken genome using human PNPLA sequences, and performed PCR to amplify and sequence orthologous cDNAs. Full-length cDNA sequences of galline PNPLA2/ATGL, PNPLA4, -7, -8, -9, and the activator protein CGI-58, as well as partial cDNA sequences of avian PNPLA1, -3, and -6 were obtained. The high degree of sequence identities (~50 to 80%) between the avian and human orthologs suggests conservation of important enzymatic functions. Quantitation by qPCR of the transcript levels of PNPLAs and CGI-58 in 21 tissues indicates that expression patterns and levels diverge greatly between species. A particularly interesting tissue in which certain PNPLAs may contribute to physiological specialization is the extraembryonic yolk sac.

**Conclusion:** Knowledge about the exact in-vivo functions of PNPLAs in any system is still sparse. Thus, studies about the temporal expression patterns and functions of the enzymes identified here, and of other already known extracellular lipases and co-factors, in the yolk sac and embryonic tissues during embryogenesis are called for. Based on the information obtained, further studies are anticipated to provide important insights of the roles of PNPLAs in the yolk sac and embryo development.

**Background**

In egg-laying species, the oocyte's yolk is the major source of nutrients and regulatory factors for the developing embryo. The accumulation of yolk is predominantly the result of massive transport of lipids and proteins from the liver to oocytes situated within ovarian follicles [1]. In mature hens of the domesticated chicken (*Gallus gallus*), fully-grown oocytes contain up to 5 g triacylglycerols (TG) and 240 mg cholesterol, and ovulate every 25 h. In parallel to this oocyte-targeted flow, lipid homeostasis of somatic tissues including the follicular cell layers is maintained. Subsequent to fertilization of the oocyte, normal
embryo growth likewise depends on efficient nutrient transfer, i.e., mainly of lipid components, from the yolk into the embryonic circulation. These mobilization processes are maintained through concerted regulation of lipoprotein metabolism involving genes for lipases, lipid transfer proteins, lipoprotein receptors, and others. Thus, the laying hen is a prime model for delineating molecular mechanisms underlying both unidirectional (hepato-oocyte-embryo) mass lipid transfer and fine-tuned regulation of systemic lipid metabolism. Moreover, the known components of this dichotomous regulatory system are highly similar to those in mammals including man, despite the specific tasks they perform [2]. Finally, the laying hen's lipid metabolism is a remarkable paradigm for hormonal control, as estrogen directly regulates not only the hepatic expression of genes for yolk precursor synthesis (e.g., vitellogenin and very low density lipoproteins, VLDL) [3,4], but likely is also involved in the modulation of lipolytic activities and lipid transfer processes important in deposition of yolk into oocytes and subsequent embryonic yolk utilization [5]. Estrogen also induces a unique apolipoprotein residing on VLDL particles, i.e., apoVLDL-II, which inhibits VLDL-lipolysis by lipoprotein lipase (LPL) in the circulation, thereby assuring efficient transport of TG into the oocyte for subsequent use by the growing embryo [6]. Thus, to mediate the mobilization of lipids from yolk, lipolytic enzymes resistant to apoVLDL-II must exist which allow the developing embryo to efficiently access the lipid moiety of yolk lipoproteins.

Yolk mobilization to the embryo proper is mediated by the endodermal endothelial cells of the extraembryonic yolk sac enclosing the yolk during embryogenesis. These cells take up VLDL from the adjacent oocytic yolk via receptor-mediated endocytosis, degrade the particles in lysosomes, and de novo synthesize and secrete lipoproteins into the embryonic circulation. The yolk sac-derived VLDL particles subsequently serve as a source of lipid components and of important proteins in embryo development [7]. Thus, we can define four crucial steps for the ultimate utilization of lipids by the chicken embryo. These steps are, in temporal order: i) massive hormonal induction of yolk precursor synthesis in the maternal liver; ii) oocyte-directed receptor-mediated transport of yolk precursors and their limited proteolysis to form yolk; iii) mobilization of yolk components, mainly lipoproteins, via the yolk sac tissue into the embryonic circulation; and iv) finally, lipid utilization by the tissues of the developing embryo.

The flux of lipid components derived from lipid-carrying macromolecules, from the adult to the yolk, as well as from yolk to the embryo, presumably requires a large number of proteins including a set of lipid hydrolases and regulatory proteins. However, with the exception of the identification of LPL [8,9] and the delineation of circulating apoVLDL-II as inhibitor of LPL [6], to date very little is known about other lipolytic enzymes of the chicken, their genes, expression patterns, modulation and regulation, let alone their functional properties in the above described processes. In man, several patatin-like lipases were identified [10,11], but their physiological roles, with the exception of adipogenic TG-lipase (ATGL) [12,13], remain to be elucidated. The patatin-like phospholipases (PNPLAs) contain a patatin domain with lipid acyl hydrolase activity that has been described as nonspecific. Patatin was first identified in potato tubers [14], and subsequently patatin-like phospholipases have been found in pro- and eukaryotes [15]. The patatin domain contains an active site with a serine-aspartate catalytic dyad and an oxyanion hole that stabilizes the enzyme-substrate transition state [16]. The patatin domain shares a conserved core module with mammalian lipases, where the nucleophilic serine is located in a tight turn between a β-sheet and an α-helix in a well conserved β-β-α-β core structure [17] which is also present in, e.g., human cytosolic phospholipase A2 [18].

This report provides the first identification, sequence information, and expression profiling of PNPLAs and the associated activator protein (CGI-58) in the chicken. We propose that these newly identified proteins function in processes controlling the distribution and utilization of lipid components within the hepat-oocyte-embryo axis of the chicken.

Results
Identification and sequencing of novel chicken genes
To identify novel chicken patatin-like lipases, and the PNPLA2/ATGL-activating protein CGI-58, the draft chicken genomic database was queried using sequences from the human orthologs. The nomenclature of the human PNPLAs as suggested by Wilson et al. [19] is adopted throughout this text. PCR was performed to amplify the identified sequences using chicken adipose tissue cDNA as template. The resulting DNA fragments were cloned and sequenced. By this approach we obtained the full-length cDNA clones from the chicken genes corresponding to PNPLA2/ATGL, PNPLA4, PNPLA8, PNPLA9, PNPLA7, and CGI-58. In addition, we were able to clone partial cDNAs from PNPLA1, PNPLA3, and PNPLA6. The mRNA sequences of the putative chicken PNPLAs and CGI-58 were deposited in GenBank under accession numbers EU419873 (CGI-58), EU419874 (PNPLA2/ATGL), EU419875 (PNPLA3), EU419876 (PNPLA1), EU419877 (PNPLA4), EU419878 (PNPLA8), EU419879 (PNPLA9), EU419880 (PNPLA6), and EU419881 (PNPLA7).

The data concerning the newly identified chicken cDNAs and proteins are summarized, together with the available information on human orthologs, in Table 1 (for the
Table 1: Summary of key features of the patatin-like lipases and CGI-58 from chicken (Gg) and man (Hs).

| Name(s) | Chr. location Gg/Hs | Size cDNA (bp) Gg/Hs | Size protein (aa) Gg/Hs | Patin domain (aa) Gg/Hs | Identity (%) Gg vs. Hs | Accession number mRNA Gg | Accession number mRNA Hs | Function(s) |
|---------|---------------------|----------------------|-------------------------|-------------------------|------------------------|--------------------------|--------------------------|--------------|
| PNPLA1 | 26 (4p21)          | 1/1602               | 1/533                   | 15–185/16–187           | ~46                    | EU419874                 | 8986440                  | TG hydrolysis |
| PNPLA2/ATGL, iPLA2ζ | 5/1p15.5           | 1452/1515            | 483/504                 | 10–180/10–180          | 67                     | EU419874                 | 58759050                  | Lipase [11], transacylase [10] |
| PNPLA3 | 1 (2q13.31)        | 1/1446               | 1/481                   | 1/10–180               | ~49                    | EU419875                 | 17059635                  | Lipase [11], transacylase [10] |
| PNPLA4 | 1X (p22.3)         | 762/762              | 253/253                 | 6–177/6–177            | 76                     | EU419877                 | 456225                   | Lipase [11] |
| PNPLA5 | G52-like            | 1/22q13             | 1/1290                  | 1/12–182               | -                      | EU419880                 | 85397722                  | Lyso-lysophospholipid hydrolisis [37], cell signaling [34] |
| PNPLA6 | 19p13.3–13.2       | 3/3984               | 1/1327                  | 1/933–1100             | ~83                    | EU419880                 | 29821500                  | Lipase [11], transacylase [10] |
| PNPLA7 | NTE-related esterase NRE | 17q31.3             | 3975/3954              | 1324/1317               | 73                     | EU419881                 | 34531027                  | Lipase [11] |
| PNPLA8 | iPLA2γ             | 1/7q31               | 2412/2349              | 803/782                | 465–661/445–640       | EU419878                 | 7670057                  | Transacylase [10], lipase [19] |
| PNPLA9 | iPLA2G6            | 1/22q13.1            | 2391/2421              | 796/806                | 472–657/481–666       | EU419879                 | 3142699                  | Lipase [19] |
| CGI-58 | ABHD5              | 2/3p21               | 1032/1050              | 343/349                | 79                     | EU419873                 | 33469972                  | Activation of PNPLA2/ATGL [22] |

The currently known synonyms for all gene products are listed under Name(s). Chromosomal locations of the genes, size of the cDNAs and proteins (where "~" indicates partial avian sequence), location of the patatin-domain within the proteins, % identities between the chicken and human proteins ("-" is used in cases where partial avian sequence is available), accession numbers of the mRNAs [64], and functions of the proteins where known (functional data from other species are also shown here), are listed with the relevant references. Note that information on the avian PNPLAS could not be obtained, as described in the text.

The sizes of the predicted proteins, where full-length clones could be obtained, are very similar to the human proteins, lending support to the assigned designations of the galline lipases. The location of the patatin-like domain within the protein structures predicted from the cloned sequences is shown in Figure 1. In PNPLAs 1–4, the patatin domain is in the N-terminal region, while in PNPLAs 6–9 it is located towards the C-terminus. We were unable to sequence the cDNA encoding the entire patatin domain of PNPLA3, but the high degree of similarity of the identified partial cDNA sequence with that of human PNPLA3[10] indicates the presence of the avian gene on chicken chromosome 1. The other chicken genes were found on chromosomes 5 (PNPLA2/ATGL), 1 (PNPLA4, -6, and -9), 17 (PNPLA7), 26 (PNPLA1), and 2 (CGI-58). PNPLA6 was cloned from an unidentified chromosome. The amino acid alignment of the patatin domains of the eight cloned sequenced patatin-like lipases with N-terminus on the left. The sequence identity among the domains is low, but importantly, the active site motifs are well conserved. On the other hand, the high levels of identity with the human orthologs support the notion that the chicken enzymes identified here have important physiological roles.

PNPLA2/ATGL (also called desnutrin, iPLA2ζ, or TTS-2) is the key enzyme for the generation of diglycerides from TG [12,13], and is functionally conserved from yeast to man [20,21]. The enzyme is activated by the protein termed “comparative gene identification 58” (CGI-58, also known as ABHD5) [22]. Deficiency of CGI-58 in man leads to a rare autosomal recessive disease of lipid metabolism, Chanarin-Dorfman syndrome (also called neutral lipid storage disease with ichthyosis; OMIM 275630), characterized by the presence of abnormally large amounts of TG-rich lipid droplets in many tissues [23,24]. Here, we determined that the chicken CGI-58 protein is 79% identical to the human ortholog, the amino acid res-

Figure 1
Schematic representation of the identified chicken patatin-like phospholipases. The solid lines represent the sequenced patatin-like lipases with N-terminus on the left. The patatin domain is drawn in gray with active site motifs highlighted in red. Thus far non-sequenced parts of the lipases are shown with dashed lines, where the lengths are from the human orthologs. The degrees of identity of the amino acid sequences between the human orthologs and the fully or partially sequenced chicken lipases range from 49% to 83% (for details, see Table 1).
Patatin domain amino acid sequence alignment of chicken PNPLAs. Chicken patatin domains were aligned using ClustalW2. Overall, the sequences show little conservation. The active-site motifs, however, are well conserved (shown in red, as in Figure 1). The lipase consensus motif with the catalytic serine, GXSXG, is fully conserved. In addition, the active site aspartate is fully conserved within the consensus DGG-motif. These catalytic dyad residues are indicated by triangles. The valine in the oxyanion hole (the consensus sequence of the motif, (G/A)XGXXG, is indicated by the superscript rectangle) of chicken PNPLA1 corresponds to a serine in the human ortholog. The non-conserved serine (instead of glycine) of the PNPLA4-oxyanion hole is also present in the rat ortholog. The unidentified N-terminal part of PNPLA3 is indicated with blanks. Identical amino acids in all 8 proteins are marked with an asterisk (*), conservative substitutions with a colon (:), and semi-conservative substitutions with a period (.).
idues critical for the activation of PNPLA2/ATGL [22], and
the putative lipase motif are fully conserved.

PNPLA3 (also known as adiponutrin or iPLA2ε) was
shown to behave differently from PNPLA2/ATGL with
respect to regulation and cellular localization [11,25,26].
PNPLA3 is strongly suppressed upon fasting, but
PNPLA2/ATGL expression is increased. Intracellularly,
PNPLA3 localizes to membranes, whereas PNPLA2/ATGL
is cytosolic.

The human PNPLA family member PNPLA1 has not been
fully cloned nor its function studied [11,19]. We were
unable to obtain the full-length clone of chicken PNPLA1
cDNA, and PCR with several primer pairs was unsuccess-
f ul; however, sequence encoding the patatin domain
could be obtained. Finally, we could not find any ESTs rel-

ev ant to PNPLA1 in the chicken EST-databases [27,28].
Equally, we could not obtain evidence for the existence of
PNPLA5 (also termed GS2-like) in the chicken, since
the chicken sequence databases available contain no DNA or
protein sequence similar to the human or other known
orthologs. Immunoprecipitated human PNPLA5 showed
lipase activity, and when overexpressed it functioned to
decrease intracellular TGs [11].

PNPLA4, also called gene sequence 2 (GS2) or iPLA2η,
was demonstrated to be expressed in essentially all
human tissues and to lipolyze TGs [10]. To date, a murine
PNPLA4 ortholog has not been reported.

Of the two reportedly unique members of the human
patatin-like family [19], PNPLA8 (iPLA2γ) is ubiquitously
expressed at moderate levels and reported to be tran-
siently upregulated during early differentiation of human
adipocytes. The other lipase in this group, PNPLA9, is
predominantly expressed in adipose tissue and brain, and is
upregulated late during adipocyte differentiation [19].
Endogenous PNPLA9 purified from Chinese hamster
ovary cells hydrolyzes dipalmitoyl phosphatidylcholine,
and the ankyrin repeats are required for enzyme activity
[29].

PNPLA6 (also known as neuropathy target esterase, NTE)
is expressed, e.g., in human blood lymphocytes [30] and
murine brain [31] and plays a role in membrane lipid
homeostasis [32,33]. PNPLA6 was suggested to be
involved in a cell-signaling pathway controlling interac-
tions between neurons and glial cells in the developing
nervous system [34]. Human [34,35], murine [36,37],
and galline [34,38] PNPLA6 were thoroughly studied in
relation to their organophosphate-induced inactivation
and neuronal degeneration. Finally, rat PNPLA7 (also
known as NTE-related esterase or NRE), is highly
expressed in prostate, pancreas, and adipose tissue [19],
and insulin down-regulates the mouse enzyme, which
predominates in testes, skeletal and cardiac muscle, and
adipose tissue [39]. The primary sequences of PNPLA6
and -7 have a high degree of identity; their similar features
indicate conserved functions. PNPLA7 was suggested to
have NTE-related esterase activity [40,41], whereas a more
recent study [39] showed that PNPLA7 is a lysophosphol-

Based on the above results, particularly related to the pata-
tin domains, we analyzed whether the avian homologs
also cluster in highly related subgroups, as was reported
for the mammalian PNPLAs [19]. The phylogenetic tree
shown in Figure 3 indicates that the relationships between
the patatin domains of chicken PNPLA2/ATGL, PNPLA1,
-3 and -4 are such that they form a distinct subfamily.
While in man, PNPLAs 5 and 4 also belong to this family
[19], a chicken PNPLA5 homologue could not be identi-
fied. A separate subfamily consists of PNPLA6 and -7, and
another is made up of PNPLA8 and -9, again in analogy
similar to the situation in man [19]. Importantly, the phy-
logenetic tree generated by analysis of the patatin domain
sequences is in agreement with the sizes of the entire pro-
teins and the position of the patatin domains within them
(cf. Figures 1 and 3). Furthermore, the residues within the
oxyanion hole and the motifs containing the catalytic ser-
ine are more highly conserved within the individual
(sub)families than between them (Figure 2).

An alignment of the core modules of galline and human
PNPLAs is shown in Figure 4. Within the PNPLA super-

Figure 3
Phylogram of the chicken PNPLA family. The phylo-
gram was calculated with ClustalW2 using the chicken pata-
tin domain amino acid sequences. The result shows that
PNPLAs 1–4 form a subfamily. PNPLA6 and PNPLA7 also
form a subfamily, as do PNPLA8 and PNPLA9. The patatin
domains of PNPLA2 and PNPLA3 are 68% identical, of
PNPLA1 and PNPLA2 51%, of PNPLA1 and PNPLA3 55%, of
PNPLA1 and 4 35%, of PNPLA2 and PNPLA4 37%, of
PNPLA3 and PNPLA4 40%, of PNPLA8 and PNPLA9 31%,
and of PNPLA6 and PNPLA7 76%. Plant patatin was used as
an out-group.
family as now known in these two species (Figure 4), the sequences in the vicinity of the active site motifs are not well conserved, with the exception of the presence of hydrophobic residues in nonvariant positions (indicated in Figure 4). In contrast, the active site motifs are well conserved within subfamilies of the two animal kingdoms. Finally, in all human and galline orthologous PNPLAs, the lengths of the stretches separating the active site motifs are identical.

**Expression profiling**

To analyze the tissue expression profiles of the above described PNPLAs, as well as of CGI-58, we measured their mRNA concentrations in 21 chicken tissues or cell types by quantitative real time PCR (qPCR) (Figures 5 and 6). The results show that in tissues highest expression levels of the PNPLAs relative to those of β-actin span from 4.64e-3 to 9.29e-2. PNPLA2/ATGL and its obligatory co-factor, CGI-58, show relatively high levels, and are expressed predominantly in adipose tissue. High expression levels of one or both of these genes were also measured in liver, brain, kidney, heart, skeletal muscle, and skin, in addition to yolk sac and testis. The expression patterns of PNPLA7 and PNPLA8 resemble each other, as do those of PNPLA6 and PNPLA9. Testis, skeletal muscle, and heart express high levels of PNPLA7 and -8, whereas PNPLA6 and -9 transcript levels are high in brain and heart. PNPLA3 expression is predominant in skeletal muscle, that of PNPLA4 in testis. In the extraembryonic yolk sac, in addition to PNPLA2/ATGL, PNPLA7 is expressed at high level. This suggests that at least these two enzymes may perform functions in the yolk sac to mobilize lipid-derived nutrients [7] for utilization by the growing embryo. In Figure 7 the data obtained in the quantitative expression analysis

![Figure 4](http://www.biomedcentral.com/1471-2164/9/281)

**Comparison of the conserved human and chicken patatin domain core modules.** The GenBank accession numbers for the chicken and human sequences are provided in Table 1. The identities between full-length patatin domains of the human and chicken PNPLA proteins are for PNPLA1, 56%; PNPLA2, 82%; PNPLA4, 74%; PNPLA6, 88%; PNPLA7, 81%; PNPLA8, 84%; PNPLA9, 74%. The partially identified patatin domain of chicken PNPLA3 is 62% identical with the human ortholog. The numbers in brackets between the active site motifs (in red) represent amino acids that are not shown in the alignment. The numbers behind the sequences show the final positions of the displayed sequences with regard to the full-length amino acid sequence. Below the sequences, the triangle indicates the location of the nucleophilic serine, the rectangle indicates the location of the oxyanion hole motif, and dots mark the nonvariant positions of predominantly hydrophobic residues. The 3 open arrows indicate regions folded as β-strands, and the cylinder indicates the region folded as α-helix in the plant (*Solanum cardiophyllum*) patatin crystal structure (ProteinDataBank entry 1OXW). The positions of these motifs relative to the nucleophilic serine, which is located in a tight turn, are indicated by the subscript numbers.
are presented as a heat map to facilitate the evaluation of the relative transcript levels. Generally, in small white and small yellow follicles (containing oocytes which have not yet entered the rapid growth phase; see Methods for details), the expression levels of the genes analyzed are low, and as the oocytes grow, the expression level, particularly of *PNPLA6*, appears to increase in the granulosa cells (Figures 6 and 7; GC F3 to GC F1). In tissues of adult animals, the peak expression levels are seen in white adipose tissue (*PNPLA2/ATGL* and *CGI-58*), brain (*PNPLA9*), testis (*PNPLA8* and *PNPLA4*), heart (*PNPLA6*), and skeletal muscle (*PNPLA7* and *PNPLA3*). In addition, high levels compared with most other tissues are present in skeletal muscle (*CGI-58*, *PNPLA8*, -9, and -4), heart (*PNPLA8*, and -9), brain (*PNPLA6*), liver (*PNPLA3*), testis (*PNPLA3*), skin (*PNPLA3*), F1 granulosa cells (*PNPLA4*), and adrenal gland (*PNPLA4*).

**In silico characterization**

The avian proteins (except PNPLA3, due to the incomplete sequence information) were analyzed using *in silico* methods to characterize their properties in more detail. PNPLA2/ATGL contains a predicted nuclear localization signal (VKKAKKKL) at residues 382–389 (the corresponding sequence in human PNPLA2, VMRAKRKL, is not predicted as nuclear localization signal) PNPLA1, -6, -7, -8, and -9 have one or more predicted tyrosine kinase phosphorylation sites. Both PNPLA6 and PNPLA7 contain two putative cyclic nucleotide binding sites indicating that they may be regulated by either cAMP or cGMP. Similar to its human orthologue, chicken PNPLA9 contains several
ankyrin repeats, suggesting the potential for protein-protein interactions. The structures of CGI-58 and of all PNPLAs except PNPLA8 are predicted to be globular. Of the fully cloned PNPLAs (PNPLA2/ATGL, PNPLA4, -7, -8, and -9), only PNPLA4 is predicted to contain a signal peptide. PNPLA4 and -7 are predicted to contain transmembrane domains at residues 7–26 and 31–53, respectively. Human PNPLA6 was not predicted to contain a membrane spanning domain, but biochemical evidence suggests that its catalytic domain is associated with membranes in neurons [42]. Based on the almost complete identity of the core module sequence to that of human PNPLA6 (Figure 4), this may also be the case for the chicken enzyme. N-glycosylation sites are found in each of the proteins; within both PNPLA2/ATGL and PNPLA4, one N-glycosylation site is located at the N-terminal boundary of the patatin domain, and in PNPLA9 it is close to the C-terminal boundary, respectively.

**Discussion**

This is the first study providing insights into the avian patatin domain-containing family of proteins whose mammalian orthologs are known to be lipases that act in several critical physiological processes. The significant degree of sequence conservation for the proposed PNPLAs and CGI-58 proteins in chicken to those of known human proteins lends strong support to the notion that these proteins play critical roles in avian lipid biology. While the catalytic mechanism of most lipases proceeds through the nucleophilic attack of a serine-histidine-aspartate triad [17] and is reminiscent of serine proteases, the patatin family of enzymes operates via a serine-aspartate dyad. The serine of this dyad is located in a so-called nucleophilic elbow, which itself is part of a region suggested by Schneider et al. [17] to represent an ancestral sequence module, i.e., one found in both the patatin family (harboring a catalytic dyad) and other lipases, general esterases, and (lyso)phospholipases (operating via a triad). This sequence module, consisting of 50–70 residues form-
ing the $\beta_2 - \beta_1 - \alpha_1 - \beta_1$ core (Figure 4), is sometimes interrupted by inserts that may have arisen during evolution [17]. The characteristic nucleophilic elbow of general esterases is located in the loop between the end of the second $\beta$-strand and the start of the $\alpha$-helix. As shown in Figure 4, the overall structure of the ancestral module clearly is present in the chicken’s patatin-like lipases, and the insert lengths are identical between the human and chicken homologue in each of the seven members for which this information could be obtained. Importantly, the active site residues are highly conserved. In addition, in the primary sequence they are flanked by hydrophilic regions.

As revealed by crystal structural analysis, the active site serine-aspartate dyad of the plant patatin [16] and human cytosolic phospholipase $A_2$ is located in a deep cleft at the bottom of a funnel [18]. The surface of this funnel is predominantly hydrophobic so as to allow access of fatty acid moieties of substrates. The two glycines in the lipase motif (GXSXG) are structurally essential for the tight turn of the nucleophilic elbow.

As in the murine protein, the protein predicted for the chicken PNPLA2/ATGL contains a potential lipid binding site at residues 311–395 [43]. Importantly, this lipid binding site, unlike other portions of the protein, is as highly conserved as the patatin-like domain. A putative nuclear localization signal (NLS) (predicted at residues 382–389 in the avian sequence) is absent from the human protein, however, and none of the other known PNPLAs are predicted to harbor any NLS; thus, the significance of this observation remains unclear. In man, deficiency of PNPLA2/ATGL causes neutral lipid storage disease with myopathy (OMIM 610717) [44]. Genetic variations within the human PNPLA2/ATGL gene influence fasting free fatty acid and glucose levels as well as the risk to develop type 2 diabetes [45]. To date, five mutations in human PNPLA2/ATGL have been reported that cause neutral lipid storage disease with myopathy. One is a mutation in which a tetranucleotide duplication leads to a premature truncation of the patatin domain [46]. Fischer et al. [44] reported three patients with milder phenotypes, and described four mutant alleles. Three of the mutations are predicted to lead to truncated PNPLA2/ATGL proteins with intact patatin domains, and the fourth leads to a single amino acid substitution (P195L). The affected proline is conserved in human PNPLAs 1–5 and also in chicken PNPLAs 1–4, further indicating an important structural role of the residue.

CGI-58, an activator of PNPLA2/ATGL, belongs to the esterase/thioesterase/lipase subfamily of proteins which are structurally characterized by the presence of $\alpha/\beta$-hydrolase folds. Its interaction with PNPLA2/ATGL is required for TG hydrolysis [22]. An intrinsic lipolytic activity of CGI-58 could not be demonstrated to date [22]; however, CGI-58 may couple lipolytic degradation of cytoplasmic TG to oxidation and packaging into TG-rich lipoproteins for secretion in hepatoma cells [47]. CGI-58 reversibly binds to lipid droplets via perilipin A in the basal state [48,49], whereas PNPLA2/ATGL does not interact with perilipin A [50]. During hormone-stimulated lipolysis, perilipin A phosphorylation by protein kinase A rapidly decreases the interaction between CGI-58 and perilipin A; thus, perilipin A indirectly controls PNPLA2/ATGL activity [50]. The important role of CGI-58 in lipase activation is further underscored by the fact that deficiency of CGI-58 in man [23,24] leads to Chanarin-Dorfman syndrome, characterized by the presence of abnormally large amounts of TG-rich lipid droplets in many tissues.

**Figure 7**

Heat map showing PNPLA and CGI-58 expression profiles. The heat map was calculated from the data presented in Figures 5 and 6 using Genesis-software [63]. Red color shows high expression level, while yellow marks low expression level.
As in mammals, the predominant expression of chicken PNPLA2/ATGL and CGI-58 in adipose tissue is compatible with the high demand on TG-lipolysis in this tissue. In the chicken, certain tissues such as liver, brain, kidney, heart, skeletal muscle, and skin also show high PNPLA2/ATGL and CGI-58 mRNA abundances, largely in concordance with the sites of TG accumulation in PNPLA2/ATGL deficient patients [44]. In addition, the yolk sac of the chicken embryo shows similarly high mRNA abundances of these genes as well as that of PNPLA7. These observations suggest key roles for the gene products in embryonic yolk mobilization and utilization. PNPLA2/ATGL has been shown to be the main target for activation by CGI-58 [22]. Differences between PNPLA2/ATGL and CGI-58 expression levels may indicate that CGI-58 possibly activates other lipases as well; the mRNA expression level differences might not reflect the protein levels, however, as reported for e.g., subcutaneous and visceral adipose tissue of obese human subjects [51]. In addition, Schweiger et al. suggested that mammalian PNPLA2/ATGL likely represents the only lipase activated by CGI-58 [52]. In this context, chicken CGI-58 transcript levels are high in skeletal muscle, where PNPLA3, -7, and -8 also are highly expressed, whereas human PNPLA3 is reported to be expressed exclusively in adipose tissue [44].

The high levels of PNPLA6 and -9 in the brain and of PNPLA4 in testis, respectively, may indicate tissue specific role(s) of these enzymes. In this respect, PNPLA6 is inhibited by organophosphate compounds, leading to delayed neuropathy in man [34] and chicken [31]. Indeed, adult hens are usually used as the animal model for experimental studies of organophosphate-induced delayed neuropathy (OPIDN). The human, murine, and galline PNPLA6s have been reported to hydrolyze a number of lysophospholipids [35-37]. Recently, Chang et al. reported partial cloning of the chicken PNPLA6 cDNA [53]. These authors described a novel 3' cDNA sequence to which we add new 5' sequence information and confirm the remaining cDNA sequence reported by them. Human [42] and chicken PNPLA6 do not appear to operate through a conventional catalytic triad, as both proteins contain two aspartate residues, rather than a histidine residue, in addition to the nucleophilic serine. It is interesting to note that while PNPLA6 and -7 are a pair forming one patatin subfamily, and PNPLA8 and -9 form another (cf. Figure 4), expression levels of PNPLA6 and -9 are high in brain, and those of PNPLA7 and -8 in skeletal muscle. This may point to evolution of the two pairs towards performing non-redundant functions in different tissues. In heart, co-expression of PNPLAs 6–9 may indicate the particularly high and complex energy demand of different classes of myocytes.

Currently, we have no evidence that PNPLA5 exists in chicken. We failed to detect any DNA or protein sequence similar to the human or other known orthologs in the chicken sequence databases available. Likewise, we could not find any relevant ESTs in the available chicken EST-databases [27,28]. Lake et al. [11] used qPCR to show that PNPLA5 mRNA abundance was greatest in lung, epididymal fat, and brown adipose tissue, but that these expression levels were also ~10000-fold lower than those of PNPLA2/ATGL or PNPLA3 in these same tissues, and undetectable by Northern-blotting [11]. PNPLA5 was induced in the liver of ob/ob mice, indicating that the regulation of PNPLA5 resembles that of genes involved in hepatic lipogenesis rather than lipolysis [11]. However, it was undetectable in livers of wild-type C57Bl/6 mice, and the human ortholog was found almost exclusively in brain [19]. In this context, the human PNPLA3, PNPLA5 and PNPLA9 loci are syntenic on human chromosome 22q13, and the galline PNPLA3 and PNPLA9 loci on chromosome 1. Further studies are required to clarify whether galline PNPLA5 is syntenic with PNPLA3 and PNPLA9, but lies in a region with lacking sequence information, or is in fact absent from the entire chicken genome. Finally, our results on galline PNPLA1 are in line with the results obtained with PNPLA1 from man [22] and mouse [11] in that only partial cDNA sequence could be obtained, and attempts to generate qPCR products, even with several sets of primers, failed. Taken together, the available data suggest that PNPLA1 may not be expressed at detectable levels in any of the three species.

Overall, we note that the expression patterns of several members of the patatin-like lipase family vary significantly in the different species studied to date. For instance, PNPLA3 mRNA levels are high in foetal and adult human liver [11], but not in murine liver (Figure 2B in [11]), and is predicted to be high in chicken skeletal muscle (Figure 6), a tissue which in the mouse does not express the enzyme [11]. PNPLA4 shows considerable expression in human heart and skeletal muscle [11], whereas its expression is moderate in chicken heart and skeletal muscle and greatest in the testis (Figure 6). Furthermore, PNPLA5 expression is high in human brain [11], but not in murine brain [11], whereas expression is high in the lung of mice [11], but not of man [11]. On the other hand, a notable exception to these examples is PNPLA2/ATGL, whose expression in adipose tissue consistently prevails over that in other tissues in all species. Since preliminary results (J. Schatte and A. Hermetter, personal communication) indicate that chicken PNPLA2/ATGL indeed possesses TG-lipase activity that is enhanced by CGI-58, it is likely that also the other PNPLA genes have important in-vivo roles in the chicken. Another tissue with significant expression of PNPLA2/ATGL (and of PNPLA7) is the yolk sac of the avian embryo, where lipases likely have significant func-
tions in the mobilization of lipid components from yolk for utilization by the embryo. In this context, Kronenberger et al. [39] have provided strong evidence that murine PNPLA7 is a lysophospholipase that is regulated by nutritional status and insulin.

Major transformations in yolk lipid composition occur during the transport across the yolk sac, an extraembryonic structure consisting of an outer mesoderm of flattened support cells and an inner layer of endodermal endothelial cells (EECs). The EECs are responsible for yolk absorption and secretion of de novo synthesized lipids and lipoproteins into capillaries emanating from villi on the basal surface of the EECs [5]. Thus, the chick embryo’s yolk sac functions in lipid transport highly analogous to the mammalian placenta in terms of nutrient provision to the embryo, and/or to the processes of intestinal lipid absorption and secretion. Following uptake of lipids into the yolk sac, almost all unesterified yolk cholesterol (80% of total cholesterol) is esterified, which then amounts to 81% of the total cholesterol in the yolk sac. One striking observation associated with lipid metabolism in the avian embryo is that the proportions of 20:4n-6 and 22:6n-3 fatty acids progressively increase during transit from yolk to the embryonic plasma. Lipolytic and re-esterification processes involving lipases lead to the almost exclusive presence of 22:6n-3 fatty acid in the phospholipid fraction of yolk, but interestingly, 22:6n-3 is subsequently present in the embryonic plasma’s TG-rich lipoproteins, which originate in the EECs. There is an almost 60-fold enrichment of 22:6n-3 from yolk TG to plasma TG [54]: 20:4n-6 preferentially distributes to phospholipids in yolk and embryonic plasma, with much smaller changes in concentrations between the fractions than observed for 22:6n-3. These and other observations [5] are compatible with the involvement of multiple hydrolytic activities in cholesterol esterification, desaturation/elongation reactions, translocation of 22:6n-3 from phospholipids to TG, and in the overall conversion of yolk lipid components to plasma lipoproteins that supply the developing embryonic organs via specific uptake mechanisms.

Future studies will address the detailed temporal expression patterns of the patatin-like putative lipases identified, and of other already known extracellular lipases and cofactors, in the yolk sac and the embryonic tissues during embryonic development. Knowledge about the exact in vivo functions of these enzymes in any system is still sparse. Based on the information gained here, it is reasonable to anticipate important insights of general relevance through exploitation of the advantages of the chick system [55,56].

Conclusion

Data mining of the draft genome of Gallus gallus combined with cDNA cloning and tissue expression analysis by quantitative PCR have resulted in the first identification of hitherto unknown putative lipolytic enzymes in this powerful experimental system. Comparison of findings in birds, which split from the mammalian lineage about 310 million years ago, with those in mammals provides additional analytical power. This fact is demonstrated here for the gene family encoding patatin domain-containing proteins which putatively function as lipases. Future studies in the chicken may reveal important features shared by this gene family and their products in different animal phyla.

Methods

Animals and tissue samples

Derco white laying hens (30–40 weeks old) and roosters were purchased from Heindl Co. (Vienna, Austria) and maintained on layer’s mash with free access to water and feed under a daily light period of 14 h. Fertilized chicken eggs were incubated under standard conditions for temperature (38 °C) and humidity (70%). The eggs were removed from the incubator after 11 days of incubation, and the shell was cut to expose the yolk sac membrane. The yolk sac membranes were excised and washed with ice-cold phosphate-buffered saline (PBS) and subsequently used for RNA extraction as described below. The preovulatory small white (less than 5-mm diameter, without yolk) and small yellow follicles (5–12-mm diameter, with yolk) form a pool from which the hierarchical follicles (F1–F7) develop. The F1 follicle is the largest and most mature follicle (to be ovulated on collection day), while higher numbered follicles are progressively smaller and less mature. Granulosa cells were isolated from F5–F7 follicles and washed with PBS [57]. Other chicken tissue samples were immediately frozen in liquid nitrogen after collection of samples or used for RNA extraction. White adipose tissue was obtained from the abdominal cavity.

Total RNA extraction, cDNA synthesis, and sequencing

Chicken total RNA was extracted from tissue using Nucleospin RNA II -kit (Macherey-Nagel) according to instructions from manufacturer. When tissue samples were not immediately used for RNA extraction, lysis buffer with chaotropic ions was added prior to freezing to stabilize RNA. All tissues used were collected from mature hens except testis, which was from mature roosters. Yolk sac and granulosa cells were prepared as described above. Single-stranded cDNA was synthesized using SuperScript II reverse transcriptase (Invitrogen) and Oligo(dT)10 -primer. Patatin-like lipase genes were searched for in the draft chicken genomic sequence database [58]. Several primer pairs were designed to produce overlapping fragments, and finally the pairs shown in Table 2 were used to...
clone the indicated cDNAs. PCR amplification was performed with a T3000 Thermocycler (Biometra) with touch-down program using Phusion Hot Start- (Finnzymes), DyNAzyme EXT- (Finnzymes), or PfuTurbo Cx Hotstart - (Stratagene) DNA polymerase with chicken adipose tissue cDNA as template. In touch-down PCR, the following conditions were used during the amplification cycles: 3 cycles at annealing temperature 3°C above the melting temperature of the primer with lower value; 3 cycles at the melting temperature; 34 cycles at 3°C below the melting temperature. Other steps of the PCR were as follows: +95°C for 2 min; cycles: +95°C for 30 s, annealing for 30 s, +72°C for 1 min/kb; +72°C for 10 min. The amplified products were subjected to agarose gel electrophoresis (1%) and stained with ethidium bromide. Subsequently, the PCR product was excised from the gel and DNA was purified with QIAquick Gel Extraction Kit (Qiagen). If Phusion or PfuTurbo polymerase was used in the PCR, a tailing reaction was performed. 7 μl purified PCR product was incubated for 30 min at +70°C with 1 μl 2 mM dATP, 1 μl 10× PCR buffer, and 1 μl (1 U/ml) Taq DNA polymerase (Roche). Next, the DNA was cloned into the pCR2.1 TOPO -vector with the TOPO TA Cloning -kit (Invitrogen), transformed into the chemically competent TOP10F E. coli bacterial strain (Invitrogen), and plated on Luria-Bertani plates containing 50 μg/ml kanamycin and 40 μg/ml X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactoside). Insert-containing bacterial clones were screened with colony PCR using the above described PCR conditions and primers. Positive clones were incubated overnight +37°C in Luria-Bertani medium containing 50 μg/ml ampicillin, and plasmid DNA was purified with Fast-Plasmid Mini -kit (Eppendorf). DNA sequencing was performed by VBC-Biotech Service GmbH (Vienna, Austria).

**Nucleotide sequence accession numbers**

The mRNA sequences of the chicken PNPLAs and CGI-58 were deposited in GenBank under accession numbers: EU419873 for CGI-58, EU419874 for PNPLA2/ATGL, EU419875 for PNPLA3, EU419876 for PNPLA1, EU419877 for PNPLA4, EU419878 for PNPLA8, EU419879 for PNPLA9, EU419880 for PNPLA6, and EU419881 for PNPLA7.

**Quantitative real time PCR**

Quantitative real time PCR (qPCR) was performed with the LightCycler 480 system (Roche) using LightCycler FastStart DNA Master SYBR Green I -kit (Roche) according to the manufacturer’s instructions. The qPCR conditions were as follows: +98°C for 10 min; 45 amplification cycles at +98°C for 10 s, annealing for 10 s (5°C above melting temperature of the primer with lower value), elongation at +72°C for 14 to 17 s (25 bp/s + 2 s), measurement of fluorescence at +79–91°C for 1 s (see Table 3). After amplification, melting curve analysis was performed as follows: +98°C for 10 s; annealing temperature for 20 s; continuous temperature gradient to +98°C with 5 acquisitions/s. The tissue cDNA samples (from adult animals and the indicated tissues and cells) were diluted 1/20 with water, and the same cDNA dilution was used for all qPCR reactions. A fresh 10⁻¹ to 10⁻⁹ serial dilution was prepared from each target gene to be analyzed starting from the 1/20 dilution of a purified PCR product, and every gene was measured twice independently with dupli-

---

### Table 2: Primers used for the cloning of chicken cDNAs.

| Gene | Forward/Reverse | Sequence (5’-3’) | Melting temperature (°C) |
|------|----------------|-----------------|-------------------------|
| PNPLA1 | Forward | ATGGTCGAGAGGAGCTGGG | 64 |
| PNPLA1 | Reverse | TGGTGATGAGGTGAGAACGG | 64 |
| PNPLA2 | Forward | ATGTTCCCTTTGGACTCGC | 59 |
| PNPLA2 | Reverse | TCAGAAGACTGCGAGCGACG | 62 |
| PNPLA3 | Forward | TGGCCCAAGAACCTAGAAAGC | 60 |
| PNPLA3 | Reverse | AAGCCGCGAGGCTTAGAAACG | 60 |
| PNPLA4 | Forward | AGTAAAGGTGCTAACTATCAT | 56 |
| PNPLA4 | Reverse | CAACACCTAGCTAGGGGG | 60 |
| PNPLA5 | Forward | GTGTGGGACACTTGGGAAGC | 60 |
| PNPLA5 | Reverse | ATAGATCTCAGGAACTTG | 53 |
| PNPLA7 | Forward | ATGGAGGAAGAGGCAAGGGCACC | 64 |
| PNPLA7 | Reverse | CTAGGCGTGGCTTCCCTGGTCGC | 68 |
| PNPLA8 | Forward | ATGCAGTCTTGGTCTCTGAG | 55 |
| PNPLA8 | Reverse | GCCATAGTGATCCCATGAAATTGG | 57 |
| PNPLA9 | Forward | TACGAGTCTCAGGGGGCCCTT | 66 |
| PNPLA9 | Reverse | TCAGCGCAGAGATCTGACCCAG | 64 |
| CGI-58 | Forward | ATGGGCGAGAGGAGGCTCGCAG | 70 |
| CGI-58 | Reverse | TCAGCCACAGAACTCATAGATG | 58 |
cate samples. From the serial dilution, $10^{-4}$ to $10^{-8}$ dilutions were used as an internal standard. As housekeeping genes, we measured the mRNA expression levels of chicken $\beta$-actin, 5-aminolevuline synthase (ALAS), and porphobilinogen deaminase (PBGD). The qPCR primers used are shown in Table 3. In qPCR, every gene had PCR efficiencies ranging from 1.926 to 1.972, as calculated from the internal standard; thus, no efficiency correlation was performed. The LightCycler 480 Software (release 1.1.0.0520) with absolute quantification was used to calculate the concentrations and standard deviations of the samples. The concentration of the target gene was divided by the concentration of the housekeeping gene thus showing the relative expression of the mRNA in the tissue. This calculation was performed for all tissues analyzed. Absolute quantification was used to calculate the concentrations and standard deviations of the samples. The concentrations of the target gene were divided by the concentrations of the housekeeping gene thus showing the relative expression of the mRNA in the tissue. This calculation was performed for all tissues analyzed. Standard deviations were calculated by multiplying the obtained relative value with the standard deviation of the target. The resulting relative and standard deviation values were scaled to a range of 0–10 including the standard deviations. Quantitative PCR was not successful with PNPLA1. Specificity of the amplification reactions was confirmed by sequencing of the qPCR products.

### Table 3: Primers used for the qPCR analyses.

| Gene   | Forward/Reverse | Sequence (5'-3') | Melting temperature (°C); Temperature of fluorescence measurement (°C) |
|--------|----------------|-----------------|---------------------------------------------------------------|
| PNPLA2 | Forward        | CAGCACCCTTTATCCCTGTTCTAC | 60; 83                                                        |
| PNPLA2 | Reverse        | AATTGGATGCTTGGATTGGTG | 54                                                            |
| PNPLA3 | Forward        | GTTGTCAGGCAATTTATGCTGT | 57; 82                                                        |
| PNPLA3 | Reverse        | ATCACACTCCCCACAGCAAAAG | 57                                                            |
| PNPLA4 | Forward        | ATGCTGGAAATAGGCAACTTC | 57; 79                                                        |
| PNPLA4 | Reverse        | CTTGTTGCTGGAACATTAGGC | 58                                                            |
| PNPLA6 | Forward        | CACCCGTTGAGTGGCTCAACATG | 62; 91                                                        |
| PNPLA6 | Reverse        | CTCCCTGACGTTCTTCTAC | 62                                                            |
| PNPLA7 | Forward        | TGTCCAGAAGCCACAGAC | 59; 86                                                        |
| PNPLA7 | Reverse        | CTGCTTTCTGCTGCTTAC | 59                                                            |
| PNPLA8 | Forward        | ACTGTGGCAGGCCATTAGAC | 59; 84                                                        |
| PNPLA8 | Reverse        | TTTCATAGCCACCCGACACC | 57                                                            |
| PNPLA9 | Forward        | AAGGACATGTTCTGTTCTTCT | 59; 88                                                        |
| PNPLA9 | Reverse        | GCTCAGCTCTCGCCTCTTCT | 59                                                            |
| CGI-58 | Forward        | GATTCCTGGCTGGCTCTACA | 59; 82                                                        |
| CGI-58 | Reverse        | CGCTGAAAGGCTTAGACC | 59                                                            |
| $\beta$-actin | Forward | AGCTATGAACCTCCCTGATGG | 57; 84                                                        |
| $\beta$-actin | Reverse | ATCTCCTTCTGCTCCCTCTC | 57                                                            |
| ALAS   | Forward        | GGCAGCTCAGATGACACCAAG | 62; 82                                                        |
| ALAS   | Reverse        | CGGCTTTTGCTCCCTCATAATC | 61                                                            |
| PBGD   | Forward        | AACTGTGGGAAAAGCCTACAG | 57; 82                                                        |
| PBGD   | Reverse        | GGCCTCAGGAGCTGACCTATG | 61                                                            |

### Abbreviations
TG: Triacylglycerol; PNPLA: Patatin-like phospholipase; iPLA2: Calcium-independent phospholipase A2; qPCR: Quantitative real time PCR; CGI-58: Comparative gene identification 58; VLDL: Very low density lipoprotein; LPL: Lipoamidase; ATGL: adipose triglyceride lipase; GC: Granulosa cell; EEC: Endodermal endothelial cell.

### Authors’ contributions
WJS designed the study, participated in the interpretation of the data, advised in the design of data presentation, and contributed to the final version of the manuscript. JS participated in the study design, performed the experiments with the assistance of GJ, contributed to the interpretation of the data, and wrote the manuscript draft. MH provided the preparations of tissues and cells used in the study. JN contributed to the design and interpretation of the data and items to be included in the Discussion. All authors made suggestions to drafts, and read and approved the final manuscript.

### In silico characterization
The obtained sequences were analyzed using the PredictProtein [59], and SignalP [60]. Multiple sequence alignment and phylogenetic tree calculation were performed using ClustalW2 [61]. Transmembrane helices were predicted using TMHMM 2.0 [62].
Additional material

**Additional file 1**

Click here for file
[http://www.biomedcentral.com/content-supplementary/1471-2164-9-281-S1.pdf](http://www.biomedcentral.com/content-supplementary/1471-2164-9-281-S1.pdf)

**Acknowledgements**

We are grateful to Dr. Zlatko Trajanoski, University of Graz and Dr. Hubert Hackl for help with data presentation, and to Astrid Pentz, B.Sc., for technical assistance. These studies were supported by the grant “GOLDII - Genomics of Lipid-Associated Disorders-II”, which is part of the Austrian Genome Project “GEN-AU Genome Research in Austria” and is funded by the Austrian Ministry for Education, Research, and Culture, and by a grant from The Austrian Research Foundation (FWF P20018). JS was in part supported by Fellowship grants from the Academy of Finland (Nr 209723 and Nr 114687).

**References**

1. Walzem RL: Lipoproteins and the laying hen: form follows function. Poult Avian Biol Rev 1996, 7:31-64.

2. Schneider WJ, Osanger A, Waclawek M, Nimpp J: Oocyte growth in the chicken: receptors and more. Biol Chem 1998, 379:965-971.

3. Bergink EW, Wallace RA: Estrogen-induced synthesis of yolk proteins in roosters. Am Zool 1974, 14:117-1193.

4. Kirchgessner TG, Heinemann C, Svenson KL, Gordon DA, Nicosia M, Lebherz HG, Luisi AJ, Williams DL: Regulation of chicken apolipoprotein B: cloning, tissue distribution, and estrogen induction of mRNA. Gene 1987, 59:241-251.

5. Speake BK, Murray AM, Noble RC: Transport and transformation of yolk lipids during development of the avian embryo. Prog Lipid Res 1998, 37:1-32.

6. Schneider WJ, Carroll R, Severson DL, Nimpp J: Apolipoprotein VLDL-II inhibits lipolysis of triglyceride-rich lipoproteins in the laying hen. J Lipid Res 1990, 31:507-518.

7. Hermann PM, Mahon MG, Lindstedt KA, Nimpp J, Schneider WJ: Lipoprotein receptors in extraembryonic tissues of the chicken. J Biol Chem 2000, 275:16837-16844.

8. Griffin H, Grant G, Perry P: Hydrolysis of plasma triacylglycerol-rich lipoproteins from immature and laying hens (Gallus domesticus) by lipoprotein lipase in vitro. Biochem J 1982, 206:647-654.

9. Bacon WL, Leclercq B, Blum JC: Difference in metabolism of very low density lipoprotein from laying hens compared to immature chicken hens. Poult Sci 1978, 57:1675-1686.

10. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW: Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 2004, 279:48968-48975.

11. Lake AC, Sun Y, Li JL, Kim JE, Johnson JW, Li D, Revett T, Shih HH, Liu W, Paulsen JE, Gimeno RE: Expression, regulation, and triglyceride hydrolyase activity of Adiponutrin family members. J Lipid Res 2005, 46:2477-2487.

12. Zimmermann R, Strauss JG, Haemmerle G, Gorkiewicz G, Birner-Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Zeche R: Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Nature 2004, 430:1383-1388.

13. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Krakty D, Wagner EF, Klingenspor M, Hoeffer G, Zeche R: Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 2006, 312:734-737.

14. Vancanneyt G, Sonnewald U, Hofgen R, Willmitzer L: Expression of a Patatin-like Protein in the Anthers of Potato and Sweet Pepper Flowers. Plant Cell 1989, 1:533-540.

15. PFAM, family: patatin (PF01734) [http://pfam.sanger.ac.uk/family?entry=PF01734&type=Family]

16. Rydel TJ, Williams JM, Krieger E, Moshiri F, Stallings WC, Brown SM, Pershing JC, Purcell JP, Alibhai MF: The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acylhydrolase with a Ser-Asp catalytic dyad. Biochemistry 2003, 42:6696-6708.

17. Schneider G, Neuberger G, Wildpaner M, Tian S, Berezovsky I, Eisenhaber F: Application of a sensitive collection heuristic for very large protein families: evolutionary relationship between adipose triglyceride lipase (ATGL) and classic mammalian lipases. BMC Bioinformatics 2006, 7:164.

18. Dessen A, Tang J, Schmidt K, Stahl M, Clark JD, Seehra J, Somers WS: Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell 1999, 97:349-360.

19. Wilson PA, Gardner SD, Lambie NM, Commans CA, Crowther DJ: Characterization of the human patatin-like phospholipase family. J Lipid Res 2006, 47:1940-1949.

20. Kurat CF, Natter K, Pestschnig J, Wolinski H, Scheuringer K, Scholz H, Zimmermann R, Leber R, Zeche R, Kohlwein SD: Obese yeast: triglyceride lipolysis is functionally conserved from mammals to yeast. J Biol Chem 2006, 281:151-150.

21. Villena JA, Roy S, Sarkadi-Nagy E, Kim KH, Sul HS: Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J Biol Chem 2004, 279:7066-7075.

22. Lass A, Zimmermann R, Haemmerle G, Riederer M, Schoiswohl G, Schweiger M, Kienesberger P, Strauss JG, Gorkiewicz G, Zeche R: Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman syndrome. Cell Metab 2006, 3:309-319.

23. Lefevre C, Jobard F, Caux F, Bouadjar B, Karaduman A, Heilig R, LakhDar H, Wollenberg A, Verret JL, Weissenbach J, Ozguc M, Lathrop M, Prud’homme JF, Fischer J: Mutations in CGI-58, the gene encoding a new protein of the esterase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 2001, 69:1002-1012.

24. Ben Selma Z, Yilmaz S, Schischmannoff PO, Blom A, Ozogul C, Laroche E, Prud’homme JF, Fischer J: Mutations in CGI-58, the gene encoding a new protein of the esterase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 2001, 69:1002-1012.

25. Liu YM, Moldes M, Bastard JP, Bruckert E, Viguerie N, Hainque B, Bassett D, Anglan D, Paillart J, Clement K: Adiponutrin: A new gene regulated by energy balance in human adipose tissue. J Cell Sci 2007, 120:2273-2276.

26. Baulande S, Lasnier F, Lucas M, Pairault J: Crystal structure of human cytosolic phospholipase A2 and its yeast homologue degrade phosphatidylcholine in living cells. J Biol Chem 2006, 281:24024-24033.

27. BBSRC ChickEST Database [http://www.chick.manchester.ac.uk/] [http://www.chickest.udel.edu/]

28. University of Delaware Chick EST Database [http://www.chickest.udel.edu/]

29. Tang J, Kriz RW, Wolfman N, Shaffer M, Seehra J, Jones SS: A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. J Biol Chem 1997, 272:8567-8575.

30. Bertocini D, Russolo A, Caroldi S, Lotti M: Neuropathy target esterase in human lymphocytes. Arch Environ Health 1985, 39:139-144.

31. Johnson MK: Organophosphorus and other inhibitors of brain ‘neurotoxic esterase’ and the development of delayed neurotoxicity in hens. Biochem J 1970, 120:523-531.

32. van Tienhoven M, Atkins J, Li Y, Glynn P: Human neuropathy target esterase catalyzes hydrolysis of membrane lipids. J Biol Chem 2002, 277:20942-20948.

33. Zachceo O, Dinsdale D, Meacoff PA, Glynn P: Neuropathy target esterase and its yeast homologue degrade phosphatidylcholine to glycerophosphocholine in living cells. J Biol Chem 2004, 279:24024-24033.

BMC Genomics 2008, 9:281 http://www.biomedcentral.com/1471-2164/9/281

Page 14 of 15 (page number not for citation purposes)
34. Glynn P. Neuropathy target esterase. Biochim Biophys Acta 1999, 1437:157-169.
35. Winrow CJ, Hemming ML, Allen DM, Quistad GB, Casida JE, Barlow C. Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity. Nat Genet 2003, 33:477-485.
36. Quistad GB, Barlow C, Winrow CJ, Sparks SE, Casida JE. Evidence that mouse brain neuropathy target esterase is a lipophorin.
37. Akiyama M, Sakai K, Ogawa M, Mc Millan JR, Sawamura D, Shimizu H: Molecular cloning and expression of chicken neuropathy target esterase activity domain. Proc Natl Acad Sci USA 2003, 100:7983-7987.
38. Atkins J, Glynn P: Adipocyte triglyceride lipase and hormone-sensitive lipase are the major lipase involved in adipose tissue triacylglycerol catabolism.
39. Atkins J, Glynn P: Adipocyte triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease.
40. Atkins J, Glynn P: Molecular cloning and expression of the C-terminal domain of mouse NTE-related esterase. Mol Cell Biochem 2000, 229:1303-1312.
41. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
42. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
43. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
44. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
45. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
46. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
47. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
48. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
49. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
50. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
51. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
52. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.
53. Atkins J, Glynn P: Adipocyte triglyceride lipase: pathway under construction. Curr Opin Lipidol 2005, 16:333-340.